Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GETUG-AFU 40: ADT +/- Darolutamide in Vulnerable De Novo Metastatic Prostate Cancer
NCT04916613Phase 3Recruiting
- Sponsor
- Unicancer
- Start
- Apr 2022
- Primary completion
- Mar 2028
- Modality
- Orthosteric Ligands
- Countries
- 12
01
Overview
A Phase 3 trial of darolutamide in prostate cancer (PCa), sponsored by Unicancer. Started Apr 2022; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04916613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916613.